Company registration number 01053899 (England and Wales)
HILLCREST (PHARMACIES) LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2025
HILLCREST (PHARMACIES) LTD
COMPANY INFORMATION
Directors
Mr JN Shah
Mr DN Shah
Mr SD Shah
Company number
01053899
Registered office
106 Holland Park Avenue
London
W11 4UA
Accountants
Aequitas Accountants Ltd
Elthorne Gate
64 High Street
Pinner
Middlesex
HA5 5QA
HILLCREST (PHARMACIES) LTD
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 6
HILLCREST (PHARMACIES) LTD
BALANCE SHEET
AS AT
30 APRIL 2025
30 April 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
3
48,485
56,814
Current assets
Stocks
230,924
231,500
Debtors
4
2,036,224
1,936,509
Cash at bank and in hand
384,226
766,806
2,651,374
2,934,815
Creditors: amounts falling due within one year
5
(297,185)
(794,590)
Net current assets
2,354,189
2,140,225
Total assets less current liabilities
2,402,674
2,197,039
Provisions for liabilities
(11,821)
(13,838)
Net assets
2,390,853
2,183,201
Capital and reserves
Called up share capital
100
100
Share premium account
9,954
9,954
Profit and loss reserves
2,380,799
2,173,147
Total equity
2,390,853
2,183,201
HILLCREST (PHARMACIES) LTD
BALANCE SHEET (CONTINUED)
AS AT
30 APRIL 2025
30 April 2025
- 2 -

For the financial year ended 30 April 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 23 September 2025 and are signed on its behalf by:
Mr SD Shah
Director
Company registration number 01053899 (England and Wales)
HILLCREST (PHARMACIES) LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2025
- 3 -
1
Accounting policies
Company information

Hillcrest (Pharmacies) Ltd is a private company limited by shares incorporated in England and Wales. The registered office is 106 Holland Park Avenue, London, W11 4UA.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover represents revenue generated from the pharmacy and is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discount, settlement discounts and volume rebates.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and equipment
15% reducing balance
Computers
15% reducing balance
Motor vehicles
10% on cost

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

HILLCREST (PHARMACIES) LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2025
1
Accounting policies
(Continued)
- 4 -

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.6
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.8
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.9
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.10
Government grants

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

 

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

HILLCREST (PHARMACIES) LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2025
1
Accounting policies
(Continued)
- 5 -
1.11

Related party exemption

The company has taken advantage of the exemption, under the terms of Financial Reporting Standard 102,' The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
15
19
3
Tangible fixed assets
Plant and equipment
Computers
Motor vehicles
Total
£
£
£
£
Cost
At 1 May 2024 and 30 April 2025
444,942
25,342
38,500
508,784
Depreciation and impairment
At 1 May 2024
431,327
9,093
11,550
451,970
Depreciation charged in the year
2,042
2,437
3,850
8,329
At 30 April 2025
433,369
11,530
15,400
460,299
Carrying amount
At 30 April 2025
11,573
13,812
23,100
48,485
At 30 April 2024
13,615
16,249
26,950
56,814
4
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
69,376
73,448
Amounts owed by group undertakings
223
500
Other debtors
1,966,625
1,862,561
2,036,224
1,936,509
HILLCREST (PHARMACIES) LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2025
- 6 -
5
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
268,169
265,182
Taxation and social security
-
0
190,284
Other creditors
29,016
339,124
297,185
794,590
6
Operating lease commitments

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

 

2025
2024
£
£
Total commitments
1,375,000
1,500,000
7
Related party transactions
Transactions with related parties

During the year the company entered into the following transactions with related parties:

2025
2024
Amounts due to related parties
£
£
Entities with common control over the company
-
295,422

The above disclosed amount is included within the other creditors due in one year. The loan is unsecured, interest free and repayable on demand.

2025
2024
Amounts due from related parties
£
£
Entities with common control over the company
1,845,702
1,803,606

The above disclosed amount is included within the other debtors due in one year. The loan is unsecured, interest free and repayable on demand.

8
Parent company

Hillcrest Holdco Limited, a company incorporated in England & Wales is the ultimate parent company.

2025-04-302024-05-01falsefalsefalse23 September 2025CCH SoftwareCCH Accounts Production 2025.200No description of principal activityMr JN ShahMr DN ShahMr SD Shah010538992024-05-012025-04-3001053899bus:Director12024-05-012025-04-3001053899bus:Director22024-05-012025-04-3001053899bus:Director32024-05-012025-04-3001053899bus:RegisteredOffice2024-05-012025-04-30010538992025-04-30010538992024-04-3001053899core:PlantMachinery2025-04-3001053899core:ComputerEquipment2025-04-3001053899core:MotorVehicles2025-04-3001053899core:PlantMachinery2024-04-3001053899core:ComputerEquipment2024-04-3001053899core:MotorVehicles2024-04-3001053899core:CurrentFinancialInstrumentscore:WithinOneYear2025-04-3001053899core:CurrentFinancialInstrumentscore:WithinOneYear2024-04-3001053899core:ShareCapital2025-04-3001053899core:ShareCapital2024-04-3001053899core:SharePremium2025-04-3001053899core:SharePremium2024-04-3001053899core:RetainedEarningsAccumulatedLosses2025-04-3001053899core:RetainedEarningsAccumulatedLosses2024-04-3001053899core:PlantMachinery2024-05-012025-04-3001053899core:ComputerEquipment2024-05-012025-04-3001053899core:MotorVehicles2024-05-012025-04-30010538992023-05-012024-04-3001053899core:PlantMachinery2024-04-3001053899core:ComputerEquipment2024-04-3001053899core:MotorVehicles2024-04-30010538992024-04-3001053899core:CurrentFinancialInstruments2025-04-3001053899core:CurrentFinancialInstruments2024-04-3001053899core:WithinOneYear2025-04-3001053899core:WithinOneYear2024-04-3001053899bus:PrivateLimitedCompanyLtd2024-05-012025-04-3001053899bus:SmallCompaniesRegimeForAccounts2024-05-012025-04-3001053899bus:FRS1022024-05-012025-04-3001053899bus:AuditExemptWithAccountantsReport2024-05-012025-04-3001053899bus:FullAccounts2024-05-012025-04-30xbrli:purexbrli:sharesiso4217:GBP